Tozorakimab PK/Target Engagement Simulator
Explore tozorakimab SC and IV dosing, monoclonal antibody exposure, and predicted systemic IL-33/sST2 inhibition using a published population PK/target-engagement framework.
Published model
Sadiq / Yu et al., BJCP 2024
Drug class
Human IgG1 anti-IL-33 monoclonal antibody
Key output
IL-33/sST2 inhibition from baseline
What this tozorakimab simulator models
The simulator combines a two-compartment monoclonal antibody PK model with a mechanistic IL-33 / soluble ST2 binding system. It is built for scientific exploration of exposure and target engagement, not individual clinical dosing.
| Component | Published value / structure | How to use it |
|---|---|---|
| Model structure | Two-compartment mAb PK | SC depot or IV input with central and peripheral disposition |
| Clearance | CL = 0.87 L/day | Base clearance in the published population PK/TE model |
| Distribution | V1 = 12.64 L; V2 = 2.61 L; Q = 0.21 L/day | Large central volume and slow distribution typical of mAb PK |
| SC absorption | Ka = 0.48 day⁻¹; F = 45% | Supports SC dosing scenarios from 30–600 mg |
| Target engagement | IL-33 / soluble ST2 binding system | Mechanistic central-compartment turnover and binding model |
| Clinical context | Healthy volunteers and mild COPD | Simulator emphasizes systemic IL-33/sST2 complex inhibition |
Simulation scenarios
SC or IV administration
Compare subcutaneous absorption with direct central input
30–600 mg dose range
Explore exposure and target engagement over the studied dose range
Q2W, Q4W, Q6W regimens
Evaluate durability of IL-33/sST2 inhibition across maintenance intervals
Body weight scenario analysis
Optional exploratory allometric scaling; off by default for paper-faithful runs
PK + TE outputs
View total tozorakimab concentration and predicted systemic target engagement
Why it matters
Anti-IL-33 programs are highly dependent on sustained pathway coverage. A PK/TE simulator makes it easier to see how dose, dosing interval, route, and body-size assumptions affect both antibody exposure and downstream systemic target engagement.
Best suited for
- Clinical pharmacology and DMPK review of anti-cytokine mAb PK
- Pharmacometrics training around PK/target-engagement models
- Scenario exploration for Q2W, Q4W, and Q6W regimen durability
- Understanding how IL-33/sST2 inhibition relates to exposure over time
Frequently asked questions
What is tozorakimab?
Tozorakimab is a human IgG1 monoclonal antibody targeting interleukin-33 (IL-33), studied in healthy volunteers and patients with mild chronic obstructive pulmonary disease.
What does this simulator predict?
The simulator predicts serum tozorakimab concentration-time profiles, last-interval Cmax, trough, AUC, terminal half-life, and systemic IL-33/sST2 target engagement after SC or IV dosing.
Which regimens can be explored?
Users can simulate 30–600 mg doses given every 2, 4, or 6 weeks, with 1–12 doses and optional exploratory body-weight scaling.
Is this for clinical decision-making?
No. The PKPDBuilder simulator is for research, education, and pharmacometric exploration. It is not intended for patient-specific clinical dosing decisions.